Moderna Inc. Archives
May. 12, 2022— by Bill Snyder Moderna’s COVID-19 vaccine is safe and generates robust immune responses in children ages 6 to 11 years, a national clinical trial co-led by Vanderbilt University Medical Center vaccine expert C. Buddy Creech, MD, MPH, has found. The two-dose vaccine (given approximately one month apart) led to antibody responses in more than...
Apr. 13, 2022—by Kristin Smart The Disney dream was deferred. Jennifer Andrews, her husband Chris Murdock, and their 6-year-old daughter Ella were all packed for a trip to Disney World in early March 2020, when they joined much of the world in having their plans upended by the COVID-19 pandemic. “We were supposed to leave on March...
Jan. 24, 2022—Vanderbilt is conducting a clinical trial to determine risk and mechanisms of allergic reactions to COVID-19 Pfizer-BioNTech mRNA vaccine among children.
Nov. 23, 2021—Researchers at Vanderbilt University Medical Center who contributed to the development of Moderna’s COVID-19 vaccine are featured in a new exhibit at the Smithsonian Institution in Washington, D.C.
Monroe Carell Jr. Children’s Hospital at Vanderbilt selected as trial site for pediatric COVID-19 vaccine
Mar. 30, 2021—Monroe Carell Jr. Children’s Hospital at Vanderbilt is set to begin a phase 2/3 clinical trial to study the safety and efficacy of the Moderna COVID-19 vaccine in children.
Jul. 15, 2020—In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.
Sep. 13, 2019—Phase 1 trial results in new approach to combat the chikungunya
Feb. 21, 2019—A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.